Latest Breaking News On - Conditions targeted - Page 1 : vimarsana.com

Amid strong headwinds, FibroGen has achieved a high market valuation. Click here to read my analysis on why I think investors should avoid FGEN stock.

United statesSan franciscoVladimir agapovFibrogen incAstellas pharma incPipeline of treatments under developmentDrug administrationa rare pediatric disease designationDrug administrationStrong headwindsHas achievedHigh marketThe biotechnologyTreatments underFast trackRare pediatric disease designationPediatric rare disease